Scisparc successfully completed production of its proprietary drug candidate sci-110 for its upcoming clinical trial on tourette syndrome

Tel aviv, israel, march 06, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (the "company" or "scisparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully manufactured clinical batches of its top-tier drug candidate sci-110 to be used in its upcoming multinational, multicenter, phase iib trial for tourette syndrome ("ts").
SPRC Ratings Summary
SPRC Quant Ranking